ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Mar 2026
Jan 2026
Latest Journal Issues
Nuclear Science and Engineering
April 2026
Nuclear Technology
February 2026
Fusion Science and Technology
Latest News
RIC panel discusses pathway to fusion commercialization
Fusion leaders at the Nuclear Regulatory Commission’s annual Regulatory Information Conference discussed the path forward for regulating the burgeoning fusion industry. The speakers discussed government and private industry initiatives in the United States and United Kingdom, with a focus on efforts shaping the near-term deployment of commercial fusion machines.
A recurring theme was the need to explain the difference between fission and fusion. Representatives from the Department of Energy and Type One Energy highlighted this as an important distinction for regulators, as it will allow fusion to undergo its own independent maturation process for developing standards and regulations in the same way that fission has. Lea Perlas, Fusion Program director at the Virginia Department of Health, said that confusion between fission and fusion has been a common cause for misplaced concerns among community members surrounding Commonwealth Fusion Systems’ proposed fusion plant site near Richmond, Va.
Jisue Moon, Kristian Myhre, Hunter Andrews, Joanna McFarlane
Nuclear Technology | Volume 209 | Number 6 | June 2023 | Pages 787-808
Critical Review | doi.org/10.1080/00295450.2022.2158666
Articles are hosted by Taylor and Francis Online.
Technitium-99m (99mTc), a widely used radioisotope, is used in tens of millions of medical diagnostic procedures annually. However, it is hard to store and must be immediately used upon production due to its short half-life (i.e., 6 h); thus, it is currently produced from 99Mo, which itself is a result of 235U fission. The majority of 99Mo supplies to U.S. patients are currently provided by foreign producers and produced using highly enriched uranium (HEU). In order to minimize the proliferation risks of HEU-based medical isotope production, the U.S. Department of Energy’s National Nuclear Security Administration has funded a program to accelerate the development of technologies to produce 99Mo without the use of HEU.
Today, the global supply of 99Mo depends on a limited number of nuclear reactors, and production has been interrupted unexpectedly since 2009 due to the fleet’s advanced age. Alternative options for 99Mo production are discussed in this paper, and one potential option is to obtain 99mTc from molten salt reactors (MSRs). A MSR is a nuclear fission reactor that can operate at or close to atmospheric pressure with liquid fuel, which allows for producing isotopes in a timely manner. In this paper, the past and current production of 99Mo via nuclear reactors is described, and the future of 99Mo production by MSRs is discussed. The behavior and chemical properties of molybdenum in fluoride salts in MSRs and the possible extraction methods are also examined in addition to the limitation of current studies.
